RxDoctor Payments DataLook up a doctor →

Philippe Nabbout, MD

Urology · Wichita, KSNPI 1811276801

Payments from drug & device makers

$183,205in general payments, 2019–2025

Across 209 payments — averaging $876.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$60K
  • Ferring Pharmaceuticals AS$58K
  • Janssen Research & Development, LLC$51K
  • Ferring Pharmaceuticals Inc.$3K
  • Urogen Pharma, Inc.$2K
  • Telix Pharmaceuticals$2K
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$5,64642%
  • Speaking & faculty fees$2,04015%
  • Food & beverage$5,39740%
  • Education$2932%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$183,205 in reported general payments places this provider in the 90th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$529,054
Medicare patients
1,183
Services billed
15,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide76$1,033,749
ErleadaApalutamide64$936,222
OrgovyxRelugolix285$743,915
GemtesaVibegron203$129,745
MyrbetriqMirabegron99$56,092
Tamsulosin Hcl715$5,067
Solifenacin Succinate90$4,017
Fesoterodine Fumarate ErFesoterodine Fumarate17$2,116
Silodosin31$1,883
Trimethoprim33$1,689
Estradiol26$1,601
Oxybutynin Chloride ErOxybutynin Chloride39$1,375
Potassium Citrate ErPotassium Citrate13$1,307
Cephalexin185$717
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$429$1,089,841175 claims
Johnson & JohnsonErleada$314$936,22264 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$26$873,660488 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 urology providers in Kansas.

Other urology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →